In August the Food and Drug Administration broadened its earlier emergency-use authorization of remdesivir, expanding its scope to include treatment of all hospitalized adult or pediatric patients with suspected or laboratory-confirmed cases of COVID-19, "irrespective of their severity of the disease."
Complete understanding of the drug's benefits continues to evolve. Three clinical trials so far have produced varying results.